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The cancer drug imatinib inhibits the tyrosine
kinases c-Abl, c-Kit, and the PDGF receptor.
Imatinib is less effective against c-Src, which
is difficult to understand because residues
interacting with imatinib in crystal structures
of Abl and c-Kit are conserved in c-Src. The
crystal structure of the c-Src kinase domain in
complex with imatinib closely resembles that
of Ablimatinib and c-Kitimatinib, and differs
significantly from the inactive ‘‘Src/CDK’’ con-
formation of the Src family kinases. Attempts
to increase the affinity of c-Src for imatinib by
swapping residues with the corresponding res-
idues in Abl have not been successful, suggest-
ing that the thermodynamicpenalty for adoption
of the imatinib-binding conformation by c-Src is
distributed over a broad region of the structure.
Two mutations that are expected to destabilize
the inactive Src/CDK conformation increase
drug sensitivity 15-fold, suggesting that the
free-energy balance between different inactive
states is a key to imatinib binding.
INTRODUCTION
c-Src and c-Abl are closely related tyrosine kinases that
are important players in cellular signal transduction and
are normally activated only in response to external signals
(Hantschel and Superti-Furga, 2004; Thomas and Brugge,
1997). c-Src was the first proto-oncogene to be identified,
and the formation of a constitutively active BCR-Abl fusion
protein is the underlying cause of disease in 95% of
patients with chronic myelogenous leukemia (CML)
(Sawyers, 2002). Imatinib (Gleevec, Novartis), an ATP-
competitive inhibitor of the kinase domain of Abl (Fig-
ure 1A), is highly successful in the treatment of CML
(Capdeville et al., 2002; Krause and Van Etten, 2005).Structure 15, 29The clinical success of imatinib is due partly to the
restricted specificity of the drug, which blocks BCR-Abl,
c-Abl, and the receptor tyrosine kinases c-Kit and the
platelet-derived growth factor receptor (PDGFR). Imatinib
has much lower affinity for other kinases, including close
relatives of Abl such as c-Src (Deininger et al., 2005).
The ability of imatinib to block c-Kit and PDGFR has en-
abled its use in the treatment of cancers that result from
the activation of these receptors, such as gastrointestinal
stromal tumors (GIST) (Buchdunger et al., 2000; Demetri
et al., 2002).
c-Abl resembles the Src family kinases, such as c-Src,
Lck, and Hck, in that its kinase activity is inhibited by the
coordinated action of SH2 and SH3 domains that are
located immediately upstreamof the kinase domain (Hant-
schel and Superti-Furga, 2004; Nagar et al., 2003). The
SH2 and SH3 domains of Src kinases dock onto the distal
surface of the inactive kinase domain and are held in place
by interactions between the SH2 domain and a phosphor-
ylated tyrosine residue in the C-terminal tail (Tyr527,
chicken c-Src numbering used throughout) (Schindler
et al., 1999; Sicheri et al., 1997; Williams et al., 1997; Xu
et al., 1997, 1999). Helix aC in the N-terminal lobe (N
lobe) of the kinase domain is swung out relative to its orien-
tation in active kinases (Knighton et al., 1991; Yamaguchi
and Hendrickson, 1996), which removes a catalytically
critical glutamate side chain (Glu310) from the active site.
The centrally located activation loop of the kinase domain
is folded into the active site, blocking substrate access.
Finally, the N- and C-terminal (C lobe) lobes of the kinase
domain close over the mouth of the kinase domain.
The inactive conformations of c-Src and Hck resemble
that seen originally in inactive cyclin-dependent kinase
(CDK) (De Bondt et al., 1993) and more recently in other
kinases, suchasAbl bound toa substrate analog (Levinson
et al., 2006) and the kinase domain of the epidermal growth
factor (EGF) receptor (Wood et al., 2004; Zhang et al.,
2006).We refer to this closely related set of inactive confor-
mations as the Src/CDK kinase domain conformation.
The kinase domain of c-Abl bound to imatinib is in an in-
active conformation that is distinct from the Src/CDK9–311, March 2007 ª2007 Elsevier Ltd All rights reserved 299
Structure
c-Src Kinase Domain Complexed with ImatinibFigure 1. The Imatinib-Binding Pocket
(A) Chemical structure of imatinib.
(B) The imatinib-binding pocket in Abl (PDB code 1OPJ) (Nagar et al., 2003). The Ca atoms of residues that interact with imatinib are depicted as
spheres. Blue, residues that are invariant among Abl, c-Src, Lck, Hck, PDGFR, and c-Kit; yellow, residues that are identical between Abl and
c-Src, but not between Abl and c-Kit or PDGFR; red, residues unique to Abl.300 Structure 15, 299–311, March 2007 ª2007 Elsevier Ltd All rights reserved
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c-Src Kinase Domain Complexed with Imatinibconformation (Nagar et al., 2002; Schindler et al., 2000).
Key differences involve helix aC,which is in an inwardly ro-
tated conformation, and the disposition of the N and C
lobes of the kinase domain, which are open. The defining
feature of the imatinib-bound conformation concerns
a conserved Asp-Phe-Gly motif (DFG motif), located at
the N-terminal end of the activation loop; the backbone
of this motif is flipped by180 with respect to its orienta-
tion in active tyrosine kinases and in the inactive Src/CDK
conformation (Figure 2).
The flipped DFG motif in the Ablimatinib complex has
the phenylalanine side chain occupying the position nor-
mally taken by the aspartate side chain (Figure 2) (Nagar
et al., 2002; Schindler et al., 2000). This is essential for
the binding of imatinib because the position of the phenyl-
alanine side chain in the active conformation overlaps with
the benzamide group of imatinib (Figure 2). The unphos-
phorylated activation loop is folded into the active site of
the kinase domain such that the central portion of the
loop mimics a bound peptide substrate. Phosphorylation
of Tyr393 (Abl-1a numbering) in the activation loop is ex-
pected to stabilize an open and active conformation of
the activation loop that is inconsistent with DFG flipping.
The essential features of the Ablimatinib complex are
also seen in a structure of the c-Kit kinase domain bound
to imatinib (Mol et al., 2004), and we refer to this DFG-
flipped conformation as the inactive ‘‘Abl/c-Kit’’ conforma-
tion. The Abl/c-Kit conformation is relevant for the physio-
logical action of the drug, as demonstrated by the location
of resistance mutations in BCR-Abl that arise in CML
patients who are being treated with imatinib (Shah et al.,
2002).
c-Src is inhibitedby imatinib to amuch lesser extent than
Abl and c-Kit, with a reported IC50 value of >100 mM,
compared to 0.025–0.2 mM for Abl and 0.4 mM for c-Kit
(Deininger et al., 2005). Since the inactive Src/CDK confor-
mation does not involve a flippedDFGmotif, the resistance
of c-Src to imatinib appears to be due to adoption of a dis-
tinctive inactive structure (Schindler et al., 2000). But one
puzzling aspect of the specificity of imatinib is that the
imatinib-sensitive kinases deviate more from each other in
sequence than theydo fromc-Src (Figures 1Band1C). The
human Abl kinase domain shares 35.1% and 36.6% se-
quence identity, respectively, with PDGFR and c-Kit. The
sequence identity between Abl and the Src family kinases
is 46% in the kinase domain. Every residue that makes
contact with the drug in Abl is either conserved in c-Src
or is replaced by a smaller residue (Figures 1B and 1C).
Out of the 21 residues that make direct contact with imati-
nib in the Ablimatinib structure, 18 residues are identical
in c-Src, but only 15 and 16 residues are identical in c-Kit
and PDGFR, respectively (Figures 1B and 1C).
One of the Src kinases, Lck, does show significant
sensitivity toward imatinib (Seggewiss et al., 2005). Since
Lck is closely related to c-Src and is expected to be struc-
turally similar, one possibility is that imatinib binds to theStructure 15, 299Src kinases without requiring the DFG flip. This is sug-
gested by the fact that imatinib binds to the Syk tyrosine
kinase, a relative of the T cell receptor-associated tyrosine
kinase ZAP-70, without a flipped DFG motif (Atwell et al.,
2004). Imatinib binds weakly to Syk (KD = 5 mM) and
does so by adopting a more compact conformation, due
to rotation around the amino group of the phenylamino-
pyrimidine (Figure 1A) (Atwell et al., 2004). Syk has a large
residue at the ‘‘gatekeeper’’ position within the active site
(Met448 in Syk; Thr in Abl, c-Src, c-Kit, and PDGFR),
which prevents imatinib from adopting an extended
conformation. A similar compact conformation of a more
flexible variant of imatinib, in which the methyl group
attached to the phenyl group is removed, is seen in com-
plex with c-Src in an active conformation (Cowan-Jacob
et al., 2005).
In this paper, we investigate the structural basis for the
resistance of the c-Src kinase domain to inhibition by im-
atinib. We show that imatinib binds 2400 times more
weakly to the c-Src kinase domain than it does to that of
Abl, consistent with previous reports (Deininger et al.,
2005). This difference is not due to a difference in auto-
phosphorylation kinetics (c-Src autophosphorylates
more readily than does Abl, which might have provided
an explanation for the difference in apparent affinity).
By determining the structure of an imatinib complex at
2.1 A˚ resolution, we show that the c-Src kinase domain
adopts the DFG-flipped conformation that is characteris-
tic of inactive Abl and c-Kit, and that imatinib is bound
in an extended conformation. From localized differences
in protein conformation and sequence we identified
sets of residues that could, in principle, increase the
sensitivity of c-Src to imatinib if swapped by the corre-
sponding residues in Abl. None of these swaps, carried
out either singly or in limited combinations, resulted in
a significant increase in affinity for imatinib, suggesting
that the imatinib resistance of c-Src is due to a distributed
set of effects.
RESULTS AND DISCUSSION
Imatinib Sensitivity of the Src Family Kinases c-Src,
Hck, and Lck
We expressed the kinase domains of Abl and three Src
family kinases, c-Src, Hck, and Lck, in E. coli (Seeliger
et al., 2005) and analyzed their sensitivity to imatinib by
using an in vitro kinase-coupled assay (Barker et al.,
1995). For c-Src, we use a kinase domain construct (resi-
dues Gln251–Leu533) that contains three extra N-terminal
residues (Gly-His-Met) originating from the tobacco etch
virus (TEV) protease cleavage site and two sequence
substitutions (T354M, E502D) relative to the sequence of
the human c-Src kinase domain. These two solvent-
exposed residues are located in the aD helix (Thr354)
and in the aH-aI loop (Glu502), and neither is close to
the imatinib-binding site (Figure 7A).(C) Sequence alignment of Abl, c-Src, Hck, Lck, PDGFR, and c-Kit kinase domains. Residues that are the same as in Abl are yellow. Residues that
interact with imatinib in the structure of Abl are in orange. Stars are color coded according to the spheres in (B).–311, March 2007 ª2007 Elsevier Ltd All rights reserved 301
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c-Src Kinase Domain Complexed with ImatinibFigure 2. The DFG Motif Flip
The surface of imatinib bound to Abl (PDB
code 1OPJ [Nagar et al., 2003]) is shown and
is superposed upon inactive c-Src in the
Src/CDK conformation (PDB code 2SRC [Xu
et al., 1999]), active Lck (PDB code 3LCK [Ya-
maguchi and Hendrickson, 1996]), the c-Src
structure in the imatinib complex (this work,
PDB code 2OIQ), and the Ablimatinib com-
plex (PDB code 1OPJ). For the c-Srcimatinib
complex, electron density for imatinib is shown
calculated before imatinib was included in the
refinement and contoured at 3s. Protein struc-
tures were aligned on the Ca atoms of the dis-
played Abl fragment (Abl residues 380–403,
PDB code 1OPJ).We measured enzymatic activity by using a 15–30 nM
kinase, 275 mM ATP, and 500 mM of the optimal peptide
substrate for Abl kinase (sequence: EAIYAAPFAKKK)
(Songyang et al., 1995). We found that the value of the
inhibition constant, Ki, for Abl kinase domain inhibition by
imatinib is 0.013 mM, whereas the c-Src kinase domain is
much less sensitive (Ki = 31 mM) (Figure 3A). Kinase
domain constructs of Lck (Ki = 0.4 mM) and Hck (Ki = 8.9
mM) show an intermediate affinity for imatinib (Figure 3A),
in agreement with a previously reported Ki value for Lck
(0.8 mM) (Seggewiss et al., 2005).
As noted previously, activation-loop phosphorylation is
likely to destabilize the DFG-flipped conformation of the
kinase domain (Schindler et al., 2000). We found that for
the Abl and Lck kinase domains the value of Ki increased
140-fold and 65-fold, respectively, upon activation-loop
phosphorylation (Figure 3A). The additional effect of
activation-loop phosphorylation on c-Src could not be
determined because the value of Ki for unphosphorylated
c-Src (31 mM) is already at the upper end of what can be
measured reliably in the enzymatic assay.
Since the enzymatic assays are carried out in the pres-
ence of ATP, we investigated whether the resistance of
c-Src to imatinib is due to rapid autophosphorylation. We
compared the rates of autophosphorylation of the Abl and
c-Src kinasedomains at 1mMand30nMprotein concentra-
tions (Figure 4). While the c-Src kinase domain shows de-
tectable levelsofphosphorylationwithin2minata1mMpro-
tein concentration, there is no detectable phosphorylation
when the protein concentration is reduced to 30 nM.Detec-
tion relied on an anti-phosphotyrosine-specific antibody,
and it is possible that the observed phosphorylation is not
on the activation-loop tyrosine. Nevertheless, the critical
point is that c-Src does not autophosphorylate significantly
under the conditions of the enzyme assay (30 nM kinase
concentration). The Abl kinase domain does not autophos-
phorylatenoticeablyateither1mMor30nMconcentrations.302 Structure 15, 299–311, March 2007 ª2007 Elsevier Ltd All rMeasurement of Binding Affinity by Calorimetry
We determined the dissociation constants, KD, of imatinib
binding to the Abl and c-Src kinase domains by isothermal
titration calorimetry (ITC), obtaining values of 0.08 mM
and >10 mM, respectively (Figures 5A and 5C). Data were
fit to a binding model that assumes one set of identical
binding sites, which yields a stoichiometry of 0.97 mole-
cules of imatinib per molecule of c-Abl and 0.84molecules
of imatinib per molecule of c-Src. Due to the solubility limit
of the drug, amore precisemeasurementwas not possible
for c-Src (Figures 5B and 5D). These measurements were
carried out by using unphosphorylated kinase domain, as
documented by mass spectrometry (data not shown),
further confirming that the affinity of c-Src for imatinib is
intrinsically low. Activation-loop phosphorylation signifi-
cantly reduces the affinity of imatinib for the Abl kinase do-
main, with KD = 1.6 mM for the Abl kinase domain that is
phosphorylated on the activation loop (Figure 5C). These
values are comparable to the values of Ki obtained for
the unphosphorylated and phosphorylated forms of the
Abl kinase domain (0.013 mM and 1.84 mM, respectively).
The Association Rate of Imatinib Is Much Lower
for c-Src than for Abl
We monitored the rate of imatinib binding to c-Abl and
c-Src by measuring the decrease in protein fluorescence
upon drug binding. Under conditions of pseudo first-order
kinetics (at least 10-fold excess of imatinib over protein),
this assay allows us to determine the rate constant for
drug binding (kon) and, by extrapolation, to estimate the
dissociation rate constant (koff) of the protein-drug
complex (Figure 6) (Fersht, 1999).
Imatinib binds to Abl 50 times faster than it does to
c-Src (kon = 0.146 mM
1 s1 for Abl versus 0.003 mM1 s1
for c-Src) (Figure 6). The values of KD derived from these
kinetic parameters are in approximate agreement with
the data from ITC and the enzymatic assays (for Abl: KDights reserved
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c-Src Kinase Domain Complexed with ImatinibFigure 3. Inhibition of Protein Kinase Activity by Imatinib
(A) Comparison of inhibitory constants (Ki) for wild-type kinase domains. Error bars indicate the uncertainties of curve fits used to calculate the drug
concentration at 50% enzyme inhibition. For sample inhibition curves, see Figure S1.
(B) Comparison of imatinib sensitivities of mutant c-Src kinase domain proteins. Mutants were grouped according to the location of the mutation
(activation loop, b3-aC loop, phosphate-binding P loop, swap of the 388RAA390 motif in c-Src to the Abl 365AAR367 motif) or destabilization of the
Src/CDK inactive conformation. The bars in blue correspond to mutations that were aimed at converting sequence motifs in c-Src into the corre-
sponding sequences in c-Abl. Bars in green correspond to mutations aimed at destabilizing the Src/CDK inactive state. The value of Ki for the
wild-type c-Src kinase domain is indicated by a vertical, red line.Structure 15, 299–311, March 2007 ª2007 Elsevier Ltd All rights reserved 303
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c-Src Kinase Domain Complexed with ImatinibFigure 4. Autophosphorylation of the
c-Abl and c-Src Kinase Domains
Detected by Staining with an Anti-Phos-
photyrosine Antibody
(A) c-Abl kinase domain at 1 mM kinase con-
centration. The primary antibody was detected
by a secondary antibody-alkaline phosphatase
stain.
(B) Autophosphorylation of c-Src at 1 mM and
30 nM kinase concentrations.by ITC 0.08 mM and 0.02 mM from the fluorescence assay;
for c-Src: KD by ITC >10 mM and 42 mM from the fluores-
cence assay). The reliability with which koff can be deter-
mined is limited due to the extrapolation of the observed
pseudo first-order rate constant (ko) to zero drug concen-
tration. A small error in the estimation of the slope will yield
a large error in koff relative to kon (Table 1). The values of koff
andKDcanonly bedeterminedaccurately for slow-binding
systems like c-Src. Neverthelesss, the dramatic difference304 Structure 15, 299–311, March 2007 ª2007 Elsevier Ltd All rigin the on rates, which are determined reliably, underscores
the impeded binding of imatinib to the c-Src kinase
domain.
Crystal Structure of the c-SrcImatinib Complex
We cocrystallized imatinib with the c-Src kinase domain
and determined the structure of the complex at 2.1 A˚ res-
olution by molecular replacement (Table 1). The unit cell is
nearly monoclinic (Table 1), but the data cannot beFigure 5. Isothermal Titration Calorime-
try of Imatinib Binding to Src and Abl
(A) Sample titration curve for imatinib binding
to the Abl kinase domain.
(B) Sample titration curve of imatinib binding to
the c-Src kinase domain. The lack of an upper
and lower baseline makes the determination of
the binding parameters less reliable in the case
of c-Src.
(C) Comparison of KD values obtained by ITC
for Abl kinase domain constructs. Leu384 in
Abl corresponds to Leu407 in c-Src. Abl was
phosphorylated on the activation loop by using
Hck and was purified (pAbl). Error bars indicate
the uncertainties of the least mean square fit of
the binding isotherm used to calculate the
dissociation constant, KD.
(D) Comparison of KD values obtained by ITC
for the c-Src kinase domain. Error bars indicate
the uncertainties of the least mean square fit of
the binding isotherm used to calculate the
dissociation constant, KD.hts reserved
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c-Src Kinase Domain Complexed with ImatinibFigure 6. Monitoring Imatinib Binding by Fluorescence
(A) Time dependence of normalized fluorescence emission intensity uponmixing of equal volumes of 100 nMAbl kinase domain with 25 mM imatinib at
25C. The transient was fit to a single equation with a sloping baseline to yield the observed rate constant, ko, of 1.84 s
1. The insert shows the
residuals of the curve fit.
(B) Kinetic transient of imatinib binding upon mixing 100 nM c-Src kinase domain with 25 mM imatinib. The fit to a single exponential with a sloping
baseline yields a value of ko of 0.125 s
1; the residuals are shown in the insert.
(C) The pseudo first-order rate constants were plotted against the imatinib concentration and were fit to a linear equation (Fersht, 1999). The slope of
the fitted line yields the association rate constant, kon, and the intercept yields the dissociation rate constant, koff.
(D) Comparison of association rate constants for c-Src and c-Abl kinase domain constructs. The dissociation constants calculated from the on and off
rates together with the errors are shown in Table S1. Error bars indicate the uncertainties of the least mean square fit to the experimental data in the
ko versus imatinib plot.processed by using P2 symmetry. We found no evidence
for a significant degree of pseudo-merohedral twinning.
The crystals have two molecules of c-Src in the asymmet-
ric unit, referred to as A and B. There is well-defined elec-
tron density for imatinib in molecule A (Figure 2), which
appears to be bound with full occupancy. The average
temperature factor for the drug is 34.4 A˚2, compared to
40.5 A˚2 for all protein atoms in molecule A. Imatinib does
not appear to be bound tomolecule B, which is in an active
conformation that is very similar to the structure of the
kinase domain of a Src-inhibitor complex described previ-
ously (Cowan-Jacob et al., 2005), and we do not discuss
it further.
Imatinib binds to c-Src in the extended ‘‘trans’’ confor-
mation seen in the c-Ablimatinib and c-Kitimatinib com-
plexes (Mol et al., 2004; Nagar et al., 2002; Schindler et al.,
2000). The structure of the imatinib-binding pocket is very
similar in the c-Src, c-Abl, and c-Kit complexes with ima-Structure 15, 29tinib (Figure S3; see the Supplemental Data available with
this article online).
Only two regions in the c-Srcimatinib complex deviate
significantly from the structure of Ablimatinib: the phos-
phate-binding loop (P loop) (c-Src residues 273–282)
and the activation loop (c-Src residues 404–425), the cen-
tral portion of which is disordered (c-Src residues 408–
420) (Figure 7). When compared to the Src/CDK inactive
conformation, helix aC in the c-Srcimatinib complex is
rotated inward, and the DFG motif is flipped. There is
also a small but significant change in the global conforma-
tion of the kinase domain. In order to accommodate the
drug, the kinase domain of c-Src opens up with respect
to the inactive Src/CDK conformation. This is illustrated
in Figure 8A, which shows a Ca-Ca difference distance
matrix that compares the c-Srcimatinib complex to
c-Src in the Src/CDK inactive form. A similar matrix for
the comparison of c-Srcimatinib to Ablimatinib is9–311, March 2007 ª2007 Elsevier Ltd All rights reserved 305
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c-Src Kinase Domain Complexed with Imatinibessentially featureless, except for a localized structural
difference around the P loop (Figure 8B).
One difference between the imatinib complexes of
c-Src and Abl concerns the location of the side chain of
an arginine residue (Arg388 in c-Src) that is replaced by
alanine in Abl and c-Kit. Reciprocally, Ala390 in c-Src is
replaced by Arg365 in Abl and Arg796 in c-Kit, and the
guanidinium groups of the three arginines are overlapped
spatially. This corresponds to the replacement of a 388Arg-
Ala-Ala390 motif in the Src kinases by an Ala-Ala-Arg motif
in Abl and c-Kit. This alteration is potentially significant
because, although the arginine side chains are in equiva-
lent positions from the point of view of the catalytic mech-
anism, the direction of Arg388 in c-Src is such that the
activation-loop tyrosine (Tyr416) would clashwith the gua-
nidinium group of Arg388 if the central portion of the
activation loop were to adopt the conformation observed
in Ablimatinib. This clash might explain the observed dis-
order of residues 408–420 in the c-Src activation loop in
the imatinib complex.
Table 1. Data Collection and Refinement Statistics
Data Collection
Space group P1
Unit cell a = 42.1 A˚, b = 63.4 A˚,
c = 74.5 A˚; a = 79.0,
b = 89.1, g = 90.1
Number of molecules/
asymmetric unit
2
X-ray source ALS 8.2.1
Wavelength (A˚) 1.00
Resolution (A˚) 50–2.07
I/sI 10.0 (2.63)
Completeness (%) 97.2 (92.5)
Rsym (%) 8.7 (29.7)
Model Refinement
Resolution (A˚) 2.07
Number of reflections
Rwork/Rfree
40,842/2,193
Rwork/Rfree 22.7/26.3
Rmsd from ideality in
bond length (A˚)
0.007
Rmsd from ideality in
angles ()
1.2
Number of protein
atoms in model
4,261
Number of drug atoms
in model
37
Number of water
molecules in model
250
Numbers in parentheses refer to the outer resolution shell
(2.07 A˚–2.14 A˚).306 Structure 15, 299–311, March 2007 ª2007 Elsevier Ltd AlThe P loop in the imatinib-bound structure of Abl is
kinked toward the C lobe of the kinase domain, and it pro-
vides a water-excluding enclosure for the drug (Schindler
et al., 2000). This conformation enables the formation of
hydrogen bonds between Tyr253 and Gln252 in the P
loop with the backbone and side chain of Asn322
(Figure 7B). Tyr253 also interacts with Phe405 in the
DFG motif in a perpendicular aromatic-aromatic interac-
tion. These two interactions are absent in c-Src, in which
the P loop is in an extended conformation.
The significance of the altered P loop conformation in
c-Src is unclear, because the P loop in the c-Kitimatinib
complex is also in an extended conformation (Mol et al.,
2004) (Figure 7C). The P loop orientation in c-Kit is stabi-
lized by a single helical turn in the activation loop, immedi-
ately after the DFG motif. A corresponding helical turn is
present in both the active and the inactive Src/Cdk confor-
mations of Src kinases (Schindler et al., 1999; Xu et al.,
1999; Yamaguchi and Hendrickson, 1996), but whether
it plays a role in the recognition of imatinib is unclear be-
cause the activation loop is disordered after the DFGmotif
in the c-Srcimatinib complex.
The c-Src Scaffold Is Resistant to Imatinib Binding
There are a total of 150 sequence differences between the
kinase domains of Abl and c-Src (Figure 1). We used these
differences to explore whether it is possible to increase
the sensitivity of c-Src to imatinib by a limited set of
mutations. We focused on sequence changes in regions
immediately adjacent to the drug-binding site that are
structurally different in the c-Srcimatinib and the
Ablimatinib complexes.
A list of the tested mutations and the corresponding
values of Ki for imatinib inhibition are shown in Figure 3B.
The specific activities of all of the mutant proteins, except
for one (F405A, in the DFGmotif), were within a factor of 10
of the wild-type-specific activity (a representative set of
kinetic data is shown in Figure S1), indicating that these
mutations (except for F405A) do not adversely affect the
structural stability of the protein. Given the central location
of Phe405 within the catalytic core of the enzyme, the
50-fold reduction in specific activity for the F405A muta-
tion is not surprising (Figure S1).
The P loop is an important site of patient resistance
mutations in BCR-Abl (Shah et al., 2002). For example,
E255K, Y253F, and Q252 H/R are mutations that are fre-
quently found in BCR-Abl (Abl-1a numbering). Of these,
Glu255 is conserved in c-Src, but Tyr253 and Gln252 in
Abl are replaced by Phe278 and Cys277, respectively, in
c-Src. Additionally, Gly250 in the Abl P loop is replaced
by Gln275 in c-Src. We replaced P loop residues in
c-Src with the corresponding residues in Abl either indi-
vidually (Q275G, F278Y; see entries 8 and 9 in Figure 3B)
or as part of larger combinations of mutations (C277Q; see
entries 12 and 17 in Figure 3B). These mutations did not
significantly increase the sensitivity of c-Src to imatinib.
As noted previously, the replacement of the 388Arg-Ala-
Ala390 motif in c-Src with an 367Ala-Ala-Arg369 motif in Abl
allows the activation-loop tyrosine (Tyr 392) to forml rights reserved
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c-Src Kinase Domain Complexed with ImatinibFigure 7. Comparison of Imatinib-Bound
Structures
(A) Structure of c-Srcimatinib (this work, PDB
code 2OIQ). The activation loop is disordered
from residue 408 to residue 420, and the phos-
phate-binding P loop is extended, leaving the
phenylalanine side chain solvent exposed.
(B) Structure of Ablimatinib (PDB code 1OPJ
[Nagar et al., 2002]). The phosphate-binding
loop is kinked toward the C lobe of the kinase,
allowing for hydrogen bonds between Tyr253
and Asn322 (not shown).
(C) Structure of c-Kitimatinib (PDB code 1T46
[Mol et al., 2004]). The phosphate-binding loop
is extended, as seen in the structure of c-Src,
and Phe600 is solvent exposed.multiple hydrogen bonds with the arginine side chain as
well as with other residues. We therefore replaced the
c-Src motif with that found in Abl (R388A, A390R), either
as a single pair of mutations (entry 13; Figure 3B) or in
combination with other mutations, including activation-
loop swaps (entries 14–17; Figure 3B). No significant
improvement in binding affinity was obtained.
The activation loops of c-Src (Asp404 to Pro425) and
Abl (Asp381 to Pro402) are the same length, but they con-
tain eight substitutions in three blocks (Figure 1). The first
block contains a single substitution, with Ser385 in Abl
replaced by Ala408 in c-Src. Ser385 is in a solvent-
exposed position in the Ablimatinib complex, and it
makes no interactions with other residues. The corre-
sponding residue in both c-Kit and PDGFR is alanine;
thus, we did not investigate this residue further.
The second block involves the segment 388MTGDT392
in Abl, which is replaced in c-Src by 411IEDNE415. We
swapped this motif in c-Src with the corresponding Abl
sequence, in isolation or in combination with other muta-
tions (entries 3–7, 11–12, and 14–17, Figure 3B), without
increasing imatinib sensitivity.Structure 15, 29The third block involves two residues, 396HA397, which
are replaced by 419RQ420 in c-Src. Ala397 in Abl and the
corresponding Gln420 in c-Src are both surface exposed
and highly variable in the kinases under consideration
(Figure 1C), and we did not consider them further.
His396 in BCR-Abl is replaced by either proline or arginine
in imatinib-resistance mutations (Shah et al., 2002), which
causes resistance because the allowed backbone torsion
angles of proline cannot be accommodated within the
inactive Abl/c-Kit conformation (Young et al., 2006). The
replacement of His396 in Abl by Arg419 in c-Src is inter-
esting, because this residue plays a role in stabilizing the
activation loop in the inactive Src/CDK conformation
(Figure S2). The R419H and R419A variants of c-Src, al-
though still not very sensitive to imatinib, have somewhat
reduced Ki values of 9.1 mM and 20.5 mM, respectively,
compared to 31 mM for wild-type c-Src (entries 1 and
2, Figure 3B). These mutations may destabilize the inac-
tive Src/CDK conformation, a point we return to in the
next section. In addition, since His396 makes a hydrogen
bond with the protein backbone in the inactive Abl/c-Kit
conformation, the R419H mutation in c-Src might be9–311, March 2007 ª2007 Elsevier Ltd All rights reserved 307
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c-Src Kinase Domain Complexed with ImatinibFigure 8. Distance Difference Matrices
(A) Left: structure of the kinase domain of c-Src in the inactive Src/CDK conformation (PDB code 2SRC). Regions that undergo structural changes
upon binding to imatinib are colored. Right: distance difference matrix between c-Src in the inactive Src/CDK conformation and the c-Srcimatinib
complex (Abl/c-Kit conformation). Each entry in this symmetrical matrix represents the difference in the distance between the corresponding Ca
atoms in the two structures. Ca atoms that come closer together upon going from the inactive Abl/c-Kit conformation to the inactive Src/CDK
conformation are indicated in yellow/red. Distances that do not changemuch are green, and distances that increase are blue. The tips of four b strands
in the N lobe of the kinase domain and the adjacent loops are colored in red (P loop: residues 274–281), orange (b3aC loop: residues 326–337), and
yellow (b4-b5 loop: residues 326–337). These strands close down on the C lobe of the kinase domain.
(B) Left: structure of Ablimatinib; loops that change their structure relative to Srcimatinib are colored. Distance difference matrix between
c-Srcimatinb and Ablimatinib (PDB code 1OPJ).expected to favor imatinib binding over the R419A
mutation.
Increase in Imatinib Affinity upon Destabilization
of the Inactive Src/CDK Conformation
As has been noted previously in an analysis of the EGF re-
ceptor kinase domain, hydrophobic side chains located in
the activation loop immediately after the DFG motif are
likely to stabilize the inactive Src/CDK conformation308 Structure 15, 299–311, March 2007 ª2007 Elsevier Ltd All(Zhang et al., 2006). We found that mutation of one such
residue in c-Src, Leu407, to glycine increases c-Src affin-
ity for imatinib by 8-fold (Figure 3B). The corresponding
mutation in Abl (L384G) had no effect on imatinib binding
(Figure 5). Another residue that is likely to stabilize the
inactive Src/CDK conformation is Trp260 in c-Src and
Hck (LaFevre-Bernt et al., 1998). Combination of the
L407G mutation with the W260A mutation further in-
creases the affinity of c-Src for imatinib to a Ki value ofrights reserved
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c-Src Kinase Domain Complexed with ImatinibFigure 9. Conformational Equilibria in c-Src and Abl
The hallmark of the Abl/c-Kit inactive state is the inward conformation of the C helix, the salt bridge between a C helix glutamate and an N lobe lysine,
and the outward orientation of the aspartate of the DFG motif. The characteristics of the Src/CDK state are the outward rotation of the C helix, which
disrupts the salt bridge with the N lobe lysine, and the inward orientation of the DFG aspartate. Imatinib binding favors the inactive Abl/c-Kit state (A*),
and activation-loop phosphorylation favors the active phosphorylated state (C*).2.0 mM, resulting in 15-fold higher affinity for imatinib with
respect to the wild-type kinase domain (Figure 3B).
Not all mutations that might be expected to destabilize
the inactive Src/CDKconformation resulted in a consistent
increase in imatinib sensitivity. There are interactions
between the loop connecting strand b3 to helix aC in the
inactive Src/c-Kit conformation (Gonfloni et al., 2000)
that are absent in the inactive Abl/c-Kit conformation.
We replaced two proline residues in the loop in c-Src
with glutamates (P299E, P304E; entries 12, 17, and 22,
Figure 3B). When introduced as an individual pair of muta-
tions, these replacements reduced the value of Ki slightly,
to 21.1 mM (entry 22), but this reduction is not apparent
when the two mutations are combined with others (entries
12 and 17).
Conclusions
In this paper, we present a crystal structure of imatinib
bound to the kinase domain of c-Src. Although imatinib
does not bind to c-Src with high affinity, the crystal struc-
ture shows that the Src kinase domain is capable of
adopting the DFG-flipped inactive conformation that is
characteristic of the Abl and c-Kit complexes with imati-
nib. Since residues that make contact with the drug are
highly conserved in c-Src, the crystal structure of the
imatinib complex makes the low affinity of c-Src for imati-
nib all the more puzzling. This situation contrasts with that
for other kinases, for which simple sequence-based
explanations are sufficient to understand imatinib resis-
tance. For example both Flt3 and Syk have bulky residues
at the gatekeeper position in the active site, and imatinib
cannot be accommodated in the extended conformation
that is presumably required for high affinity.Structure 15, 29The in vivo specificity of imatinib depends on a number
of factors, including the interplay of kinases with phospha-
tases and the allosteric effects of regulatory domains that
are not included in our study. Nevertheless, our results
make clear that the unphosphorylated kinase domain of
Src is intrinsically resistant to imatinib, which binds
2400 times less tightly to it than the Abl kinase domain,
corresponding to a 4.6 kcal/mole penalty in terms of
relative binding energy.
Our attempts to engineer imatinib sensitivity into the
c-Src kinase domain have been unsuccessful so far. We
selected residues in c-Src that are the most obvious
candidates for imposing restrictions on imatinib binding
and replaced them with the corresponding residues in
Abl. These include residues in the P loop and the acti-
vation loop, which are structurally different in the
Srcimatinib complex when compared to the Abl com-
plex. None of the residue swaps resulted in an increased
affinity for imatinib. These results suggest that the free-en-
ergy penalty for imatinib binding to c-Src arises from a dis-
tributed set of factors. It would be informative to carry out
a saturation mutagenesis screen to see if residues located
far from the imatinib-binding site could affect affinity
through allosteric mechanisms, as is the case with certain
BCR-Abl-resistance mutations (Azam et al., 2003).
The only mutations for which we see a detectable im-
provement in binding affinity are those that were designed
to destabilize the inactive Src/CDK conformation of c-Src.
We have previously shown that the Abl kinase domain can
adopt an inactive Src/CDK conformation, and we had
speculated that one set of imatinib-resistant mutations
in BCR-Abl might function by stabilizing the inactive
Src/CDK conformation relative to the inactive Abl/c-Kit9–311, March 2007 ª2007 Elsevier Ltd All rights reserved 309
Structure
c-Src Kinase Domain Complexed with Imatinibconformation (Levinson et al., 2006). In the present work,
we show that Src can adopt the inactive Abl/c-Kit confor-
mation, but that the conformational balance is tuned dif-
ferently than in Abl (Figure 9). Understanding the molecu-
lar principles that govern this free-energy balance will be
an important aspect of gaining a more complete under-
standing of kinase inhibitor specificity.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
Kinase domain constructs (human c-Abl, residues 229–512; chicken
c-Src, residues 251–533; murine Lck, residues 227–509; human Hck,
residues 166–445) were expressed as described previously for Abl and
c-Src (Seeliger et al., 2005). Genes encoding the constructs were
cloned into pET28, modified to yield an N-terminal, TEV-cleavable
His tag. Proteins were coexpressed with YopH phosphatase (Bliska
et al., 1991) and purified by immobilizedmetal ion affinity chromatogra-
phy, anion exchange chromatography, and size-exclusion chromatog-
raphy. Proteins in 20mMTris (pH8.0), 100mMNaCl, 5%glycerol, 1mM
DTTwere concentrated, frozen in liquid nitrogen, and stored at80C.
Yields of purified protein per liter of culture ranged from 15mg (c-Src
kinase domain) to 0.15mg (Lck constructs). Mutations were generated
with the QuikChange kit (Stratagene) and were confirmed by DNA se-
quencing and mass spectrometry (D. King, HHMI, UC Berkeley). Acti-
vation-loop-phosphorylated Abl kinase domain was prepared through
phosphorylation with affinity-tagged Hck kinase and ion exchange
chromatography.
Crystallization and Structure Determination
The c-Srcimatinib complex was formed in a solution of 330 mMkinase
domain, 500 mM imatinib, 5% DMSO, 20 mM Tris (pH 8.0), 100 mM
NaCl, 1 mM DTT. Using the hanging drop vapor diffusion method
(1 ml protein + 1 ml mother liquor), crystals grew overnight at 20C in
a mother liquor of 0.1 M MES (pH 6.5), 4% glycerol, 12% PEG 4000,
50 mM sodium acetate. Crystals were cryoprotected in mother liquor
plus 20% glycerol, frozen, and stored in liquid nitrogen. Diffraction
data were collected at the Advanced Light Source (Lawrence Berkeley
National Laboratory) beamline 8.2.1. Data were processed in space
group P1 (Table 1) by using DENZO and Scalepack (Otwinowski and
Minor, 1997). The structure was solved by molecular replacement by
using the kinase domain of human c-Src (PDB code 2SRC) (Xu et al.,
1999) (residues 260–520) without the C helix (residues 298–310) and
the activation loop (residues 400–425) as the template in Phaser (Mc-
Coy et al., 2005) of ccp4i. The structure was built in O (Jones et al.,
1991) and Coot (Emsley and Cowtan, 2004), and refinement of the
structure was straightforward and was conducted by using CNS
(Brunger et al., 1998).
Kinase Assays and Imatinib Inhibition
Kinase assays with a substrate peptide (Songyang et al., 1995) (se-
quence: EAIYAAPFAKKK) relied on a continuous spectrophotometric
assay (Barker et al., 1995), and imatinib titrations were performed as
described (Seeliger et al., 2005). Inhibitory constants (Ki) were calcu-
lated from the imatinib concentration that causes 50% inhibition
(IC50) according to the following relationship (ChengandPrusoff, 1973):
Ki = IC50=ð1+ ½½ATP=KMÞ; (1)
where [ATP] is the concentration of ATP in the assay (typically 275 mM)
and KM is the Michaelis constant for ATP, which was determined for
the Src and Abl wild-type kinase domains to be 70 mM; this value
was used for all mutant proteins.
Measurement of Imatinib Binding
Isothermal titration calorimetry was carried out as described (Seeliger
et al., 2005). For the fluorescence kinetics measurements, equal vol-310 Structure 15, 299–311, March 2007 ª2007 Elsevier Ltd Allumes of protein at 100 nM concentration in 50 mM Tris (pH 8.0),
100 mM NaCl, 5% glycerol, 1 mM DTT, and imatinib at concentrations
ranging from1mMto200mMin identical bufferweremixedat room tem-
perature in a rapid-mixing instrument (Applied Photophysics, Leather-
head, UK). The decrease of protein fluorescence at 350 nm upon exci-
tation at 290 nmwasmonitored on a HORIBA Jobin Yvon FluoroMax-3
(Edison, NJ) spectrofluorimeter. Each transient was measured over
10–20 half-lives with 1000–2000 time points and at least 3 repeats
per experiments. Data were fit to a single exponential with a sloping
baseline to account for photobleaching. The observed rate constant
was plotted against the final imatinib concentration and was fit to a lin-
ear function where the slope yields the binding rate constant and the
intercept yields the dissociation rate constant (Fersht, 1999).
Supplemental Data
Supplemental Data include samples of enzymatic inhibition curves
(Figure S1), an illustration of residue Arg419 stabilizing the Src inactive
conformation (Figure S2), and a comparison of the imatinib-binding
pocket in c-Src and c-Kit (Figure S3) and are available at http://
www.structure.org/cgi/content/full/15/3/299/DC1/.
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